Good MorningStocks got a boost from the Federal Reserve on Wednesday when it released its policy statement. In the
statement, the FOMC says it will aggressively dial back its bond purchasing program because its dual mandate
of employment and inflation have been met. The FOMC is indicating three interest rate hikes by the end of 2022
which is in line with the market’s expectations. The risk now is that inflation won’t respond to the policy shift
and the FOMC will be forced to act even more aggressively than it is now indicating.
On the economic front, the November retail sales figures came in much weaker than expected and reflect the
rising problem of inflation. Retail sales came in at up 0.3% versus an expectation of up 0.5% but the data does
not account for the impacts of inflation. With CPI up 6.8% for the year, the volume of sales is actually down
with the difference in the Retail Sales data made up by higher prices. Featured: Trump’s Currency Coup Exposed (Ad) 
|
Technology | | It was as if equity markets gave a collective sigh of relief yesterday after the Federal Reserve signaled it would begin “aggressive” tapering of its asset purchase program, while also aiming for three interest rate hikes in 2022. The uncertainty around just how the Fed would react to ri... Read the Full Story |
|
From Our Partners | | Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million Americans watched, but Whitney Tilson, former manager of a $200 million hedge fund, says most investors missed what it actually means.
With 1 in 3 Super Bowl viewers using buy-now-pay-later services and 40% of Americans carrying more credit card debt than savings, Tilson believes Elon's message reveals a major economic current - and a clear signal for where smart money should be positioned. | | Watch Tilson's free presentation to see what he thinks you should do now |
|
Markets | | Personal financial management platform provider MoneyLion (NYSE: ML) stock has lost nearly (-70%) of its value from its 2021 peak. The fintech envisions building a digital private banks for the working middle class and focuses on marketing heavily to the Generation-Z demographic. With an easy to use... Read the Full Story |
|
Markets | |
Like a missing dog, meme stocks have been lost but not forgotten in recent months. The collection of oft irrationally charged tickers have largely fallen out of favor in the market with most traders having (for now) moved on the next big thing. For a novelty act that loudly dominated the headlines... Read the Full Story |
|
From Our Partners | | OpenAI and Anthropic are moving closer to the public-market spotlight - and Wall Street rarely waits until the first trading day to reposition.
By the time these IPOs arrive, the obvious AI names may already be crowded and fully priced. The earlier opportunity could lie in chips, cloud infrastructure, data tools, and enterprise AI systems. One report covers 9 AI stocks - including a chip name tied to U.S. infrastructure, a cloud player with an underappreciated setup, and a data analytics business with government and enterprise exposure. | | Review the full 9-stock AI breakdown before the next wave hits |
|
Technology | |
Time to Buy the Dip in Quality Tech Companies?
Investors have been dealing with a volatile stretch in the market during the past few weeks, especially in the tech sector. Many of the big winners from earlier in the year are well off of their 52-week highs and continue to face selling pressure on ... Read the Full Story |
|
Business Services | |
ABM Plunges On Unexpected Spending Plans
Shares of ABM Industries, Incorporated (NYSE: ABM) are down nearly 10% in the wake of the Q4 earnings report and there are more reasons than one. Ultimately, the news is good but was not well received by the market. The Q4 results themselves were fine, it ... Read the Full Story |
|
From Our Partners | | This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, but that single shot started an avalanche of investigations, accusations, and conspiracy theories.
That's what you just witnessed with the death of the Ayatolla Khamenei.
Because the strikes proved how fragile things can get: billions could be lost. Seniors and the vulnerable put at risk. | | So to make it easy, Get the 2026 Retirement Survival Guide. Plain-English, step-by-step |
|
Technology | |
The unlikely meme stock is showing investors its business strategy is starting to pay off
BlackBerry (NYSE:BB) was one of the stranger companies to be part of the meme stock movement. The company is best known for its namesake mobile devices. Nevertheless, the low share price at the beginning of... Read the Full Story |
|
Retail/Wholesale | |
Blue Chip McDonald’s Still Winning The Burger Wars
After checking the latest happenings in the burger world two things have become clear. The burger and, in particular the QSR burger, the industry is doing just fine and within that McDonald’s (NYSE: MCD) stands out as the clear winne... Read the Full Story |
|
Transportation | |
There Are Reasons To Be Wary Of FedEx FQ2 Results
If you are thinking FedEx (NYSE: FDX) is going to have a strong quarter you are probably right. The company is forecasting a 10% increase in holiday deliveries that, when coupled with all the price increases, should deliver revenue growth in the ... Read the Full Story |
|
Markets | | Premium retail department store chain Nordstrom (NYSE: JWN) stock was crippled on its Q3 2021 results and forward guidance ahead of the holiday shopping season. Nordstrom Rack has been the weak spot for the retailer as it continued to face inventory issues due to supply chain constraints. The Compan... Read the Full Story |
|
Transportation | |
REV Group Slips On Supply Chain Issues
REV Group (NYSE: REVG) stock popped earlier this year on rising demand for its products across all lines. The demand led the company to raise guidance, outperform expectations, resume the dividend, and send shares to the highest levels in three years. Now, ... Read the Full Story |
|
The Early Bird Stock Of The Day Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. | | View Today's Stock Pick |
|
